UCL School of Pharmacy and partners awarded 5 million Euros to develop better medicines
19 May 2020
Professors Abdul Basit, Simon Gaisford and Drs Mine Orlu and Asma Buanz to lead UCL’s development of optimised drug therapy for human health with the Interreg 2 Seas programme.
Interreg 2 Seas is a European wide programme that is focused towards the development of innovative, research-based projects across the continent.
The UCL School of Pharmacy, in collaboration with the universities of Cambridge, Delft, Ghent, Leiden and Lille, have been awarded 5 million Euros towards advancing healthcare. From UCL, Professors Abdul Basit, Simon Gaisford and Drs Mine Orlu and Asma Buanz will lead a project which aims to improve oral drug delivery.
Success from this project can contribute towards optimising drug therapy and reducing cost burdens from hospitalisations following adverse drug effects which is estimated at €79 billion per year in Europe. The critical mass needed to unite the level of knowhow, facilities, theoretical and experimental techniques is only reached by the cross-border collaboration of world-wide leading specialists.
On behalf of the awarded team at the UCL School of Pharmacy, Professor Basit shares, “We are delighted to work alongside the whole European consortium under the Interreg 2 Seas Programme and strive to improve current treatments strategies for the benefit of patients."
Interreg 2 Seas: https://www.interreg2seas.eu/en/Site-Drug